Phoenix Biomolecular Corporation
http://www.phoenixbiomolecular.com/
"Reversing Human Aging" Scientist, Dr. Michael Fossel, Joins Science Board of Canada-US Anti-Aging Biotech Company
Predicted reversal of human aging to be possible in the next ten years
RICHMOND HILL, ON and LA JOLLA, CA, Nov. 28 /PRNewswire/ - Phoenix
Biomolecular Corporation today announced Dr. Michael Fossel as a member of its
Science Advisory Board. Dr. Fossel is one of the leaders in the field of
telomere science and human aging research worldwide. He is past Editor-in-
Chief of the Journal of Anti-Aging Medicine (renamed Rejuvenation Research);
Professor of Clinical Medicine at Michigan State University; recipient of a
National Science Foundation Fellowship; author of the text Cells, Aging, and
Human Disease, Oxford University Press, 2004; author of the book Reversing
Human Aging, William Morrow, 1996; and has published numerous reports and
review articles in the scientific literature, including the Journal of the
American Medical Association. He received his MD and PhD in neurobiology, both
from Stanford University.
"Michael has led the way in our field since the 1990s, consolidating the
early research into telomere science, and how humans age at the cellular
level," said Douglas Coyle, Phoenix's CEO. "Michael was the first scientist we
consulted with in 2003 to determine if there were other organizations working
on our approach to telomere therapy for human anti-aging. Happily, we learned
that Phoenix was alone in focusing on this particular approach, and as a
result, Phoenix was able to acquire the exclusive rights to patents for key
technology from the University of California. I am looking forward to his
continued input and insight as a Phoenix Science Advisor."
Dr. Fossel's 1996 book Reversing Human Aging, which suggested that
"telomere therapy for extending your life span will be available between 2005
and 2015," created a great deal of controversy at the time. However, continued
advances in our knowledge of human cellular biology and experimental evidence
have supported many of the predictions made in the book. For example, it is
now common practice to use telomere therapy to rejuvenate human cell lines for
use in cell therapies. And in the lab, telomere therapy is now used to
rejuvenate old skin cells to grow new patches of young skin for transplant
onto animals.
"A 70-year-old patient with bits of young skin is only the first step,"
says Coyle. "The challenge is to demonstrate telomere therapy for tissues
inside a living human body. Dr. Fossel's advisory role will help Phoenix in
its plans to demonstrate that telomere therapy can prevent and reverse many
aspects and many diseases of human aging."
About Phoenix: Phoenix is an early-stage biotech company with anti-aging
technology that, once proven, will offer the ability to rejuvenate the cells
of a living human body - with the potential to end some or all of the diseases
of aging that plague us today. The core technology, called telomere therapy,
has already been shown in repeated experiments in animals and humans to work
for cells treated outside of the body. Phoenix expects to demonstrate that
telomere therapy will also work safely and effectively when delivered to cells
within a living body. Phoenix plans to use its exclusive, patent pending
delivery technology to demonstrate telomere therapy and cellular rejuvenation
in living animals and humans, topically for skin treatment, and internally.
Phoenix has signed an exclusive license to patents from a leading biotech
lab at the University of California at San Diego (UCSD).
Phoenix has attracted the interest and participation of top-level
scientists in the field, as well as institutional support. The company has
secured fully equipped labs in La Jolla, California, close to UCSD, and plans
to begin operations there in the first quarter of 2006.
In addition, the Phoenix delivery technology is itself a platform
technology that can be used for delivering a wide range of large biomolecules
to treat aging, cancer, viral, bacterial and parasitic diseases, obesity,
genetic diseases and many other conditions. The potential to alleviate human
suffering and the potential for financial success is unprecedented.
Phoenix is a private Delaware corporation, and is currently in
discussions with private equity sources to further fund its development
program.
Risks and Uncertainties - Certain statements contained in this press
release are forward-looking statements which involve known and unknown risks,
uncertainties and other factors which may cause the actual results,
performance or achievements of Phoenix Biomolecular Corporation, or industry
results, to be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
SOURCE Phoenix Biomolecular Corporation
http://www.prnewswir...04223623&EDATE=